132 related articles for article (PubMed ID: 35219025)
1. The role of perioperative chemotherapy in primary high-grade extremity soft tissue sarcoma: a risk-stratified analysis using PERSARC.
Acem I; van Houdt WJ; Grünhagen DJ; van der Graaf WTA; Rueten-Budde AJ; Gelderblom H; Verhoef C; ; van de Sande MAJ
Eur J Cancer; 2022 Apr; 165():71-80. PubMed ID: 35219025
[TBL] [Abstract][Full Text] [Related]
2. Impact of perioperative chemotherapy and radiotherapy in patients with primary extremity soft tissue sarcoma: retrospective analysis across major histological subtypes and major reference centres.
Callegaro D; Miceli R; Bonvalot S; Ferguson P; Strauss DC; Levy A; Griffin A; Hayes AJ; Stacchiotti S; Le Pèchoux C; Smith MJ; Fiore M; Dei Tos AP; Smith HG; Catton C; Casali PG; Wunder JS; Gronchi A
Eur J Cancer; 2018 Dec; 105():19-27. PubMed ID: 30384013
[TBL] [Abstract][Full Text] [Related]
3. A prediction model for treatment decisions in high-grade extremity soft-tissue sarcomas: Personalised sarcoma care (PERSARC).
van Praag VM; Rueten-Budde AJ; Jeys LM; Laitinen MK; Pollock R; Aston W; van der Hage JA; Dijkstra PDS; Ferguson PC; Griffin AM; Willeumier JJ; Wunder JS; van de Sande MAJ; Fiocco M
Eur J Cancer; 2017 Sep; 83():313-323. PubMed ID: 28797949
[TBL] [Abstract][Full Text] [Related]
4. Multimodality treatment of undifferentiated pleomorphic soft tissue sarcoma of the extremity (eUPS) in the elderly.
Bleckman RF; Acem I; van Praag VM; Dorleijn DMJ; Verhoef C; Schrage YM; Haas RML; van de Sande MAJ; The Collaborative Persarc Research Group ;
Eur J Surg Oncol; 2022 May; 48(5):985-993. PubMed ID: 34930647
[TBL] [Abstract][Full Text] [Related]
5. Perioperative chemotherapy is not associated with improved survival in high-grade truncal sarcoma.
Yu PY; Beal EW; Hughes TM; Suarez-Kelly LP; Shelby RD; Ethun CG; Tran TB; Poultsides G; Charlson J; Gamblin TC; Tseng J; Roggin KK; Chouliaras K; Votanopoulos K; Krasnick BA; Fields RC; Pollock RE; Grignol V; Cardona K; Howard JH
J Surg Res; 2018 Nov; 231():248-256. PubMed ID: 30278937
[TBL] [Abstract][Full Text] [Related]
6. The role of Ifosfamide-doxorubicin chemotherapy in histology-specific, high grade, locally advanced soft tissue sarcoma, a 14-year experience.
Goy BW; Syed S; Padmanabhan A; Burchette RJ; Helmstedter CS
Radiother Oncol; 2021 Dec; 165():174-178. PubMed ID: 34758339
[TBL] [Abstract][Full Text] [Related]
7. The effect of adjuvant chemotherapy on the survival of patients with high-risk soft tissue sarcomas: Single center experience.
Eraslan E; Ilhan Gulesen A; Yildiz F; Tufan G; Yalcintas Arslan U; Alkis N
J BUON; 2021; 26(5):2169-2175. PubMed ID: 34761631
[TBL] [Abstract][Full Text] [Related]
8. The Influence of Personalised Sarcoma Care (PERSARC) Prediction Modelling on Clinical Decision Making in a Multidisciplinary Setting.
Hagenmaier HSF; van Beeck AGK; Haas RL; van Praag VM; van Bodegom-Vos L; van der Hage JA; Krol S; Speetjens FM; Cleven AHG; Navas A; Kroon HM; Moeri-Schimmel RG; Leyerzapf NAC; van de Sande MAJ
Sarcoma; 2021; 2021():8851354. PubMed ID: 34720664
[TBL] [Abstract][Full Text] [Related]
9. The Impact of Perioperative Chemotherapy Timing in Conjunction With Postoperative External-Beam Radiation Therapy on Extremity Soft-Tissue Sarcomas Outcome.
Mahmoud O; Dosch A; Kwon D; Pitcher JD; Conway S; Benedetto P; Fernandez G; Trent J; Temple HT; Wolfson AH
Am J Clin Oncol; 2016 Oct; 39(5):528-34. PubMed ID: 24879472
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: A Sarculator-based risk stratification analysis of the ISG-STS 1001 randomized trial.
Pasquali S; Palmerini E; Quagliuolo V; Martin-Broto J; Lopez-Pousa A; Grignani G; Brunello A; Blay JY; Tendero O; Diaz-Beveridge R; Ferraresi V; Lugowska I; Infante G; Braglia L; Merlo DF; Fontana V; Marchesi E; Donati DM; Palassini E; Bianchi G; Marrari A; Morosi C; Stacchiotti S; Bagué S; Coindre JM; Dei Tos AP; Picci P; Bruzzi P; Miceli R; Casali PG; Gronchi A
Cancer; 2022 Jan; 128(1):85-93. PubMed ID: 34643947
[TBL] [Abstract][Full Text] [Related]
11. Value of peri-operative chemotherapy in patients with CINSARC high-risk localized grade 1 or 2 soft tissue sarcoma: study protocol of the target selection phase III CHIC-STS trial.
Filleron T; Le Guellec S; Chevreau C; Cabarrou B; Lesluyes T; Lodin S; Massoubre A; Mounier M; Poublanc M; Chibon F; Valentin T
BMC Cancer; 2020 Jul; 20(1):716. PubMed ID: 32736540
[TBL] [Abstract][Full Text] [Related]
12. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
Judson I; Verweij J; Gelderblom H; Hartmann JT; Schöffski P; Blay JY; Kerst JM; Sufliarsky J; Whelan J; Hohenberger P; Krarup-Hansen A; Alcindor T; Marreaud S; Litière S; Hermans C; Fisher C; Hogendoorn PC; dei Tos AP; van der Graaf WT;
Lancet Oncol; 2014 Apr; 15(4):415-23. PubMed ID: 24618336
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapy, irradiation, and surgery for function-preserving therapy of primary extremity soft tissue sarcomas: initial treatment with ifosfamide, mitomycin, doxorubicin, and cisplatin plus granulocyte macrophage-colony-stimulating factor.
Edmonson JH; Petersen IA; Shives TC; Mahoney MR; Rock MG; Haddock MG; Sim FH; Maples WJ; O'Connor MI; Gunderson LL; Foo ML; Pritchard DJ; Buckner JC; Stafford SL
Cancer; 2002 Feb; 94(3):786-92. PubMed ID: 11857314
[TBL] [Abstract][Full Text] [Related]
14. What is the standard indication of adjuvant or neoadjuvant chemotherapy in localized soft-tissue sarcoma?
Hindi N; Martin-Broto J
Curr Opin Oncol; 2021 Jul; 33(4):329-335. PubMed ID: 33973551
[TBL] [Abstract][Full Text] [Related]
15. Real-world evidence on perioperative chemotherapy in localized soft tissue sarcoma of the extremities and trunk wall; a population-based study.
Boye K; Lobmaier I; Kobbeltvedt MR; Thorkildsen J; Taksdal I; Bjerkehagen B; Bruland ØS; Zaikova O; Sundby Hall K; Hompland I
Acta Oncol; 2022 Jul; 61(7):793-800. PubMed ID: 35698755
[TBL] [Abstract][Full Text] [Related]
16. Histological response assessment following neoadjuvant isolated limb perfusion in patients with primary, localised, high-grade soft tissue sarcoma.
Andreou D; Werner M; Pink D; Traub F; Schuler MK; Gosheger G; Jobke B; Reichardt P; Tunn PU
Int J Hyperthermia; 2016; 32(2):159-64. PubMed ID: 26670477
[TBL] [Abstract][Full Text] [Related]
17. [Responses of 109 adult soft tissue sarcoma patients to chemotherapy].
Qiu MZ; Xu F; Wang SS; Luo HY; Wang F; Li FH; Sun XF; Xu GC; Lin TY; Huang HQ; Jiang WQ; Guan ZZ; Xu RH
Ai Zheng; 2007 Dec; 26(12):1344-9. PubMed ID: 18076798
[TBL] [Abstract][Full Text] [Related]
18. External validation and adaptation of a dynamic prediction model for patients with high-grade extremity soft tissue sarcoma.
Rueten-Budde AJ; van Praag VM; van de Sande MAJ; Fiocco M;
J Surg Oncol; 2021 Mar; 123(4):1050-1056. PubMed ID: 33332599
[TBL] [Abstract][Full Text] [Related]
19. Neo-adjuvant chemotherapy for primary high-grade extremity soft tissue sarcoma.
Grobmyer SR; Maki RG; Demetri GD; Mazumdar M; Riedel E; Brennan MF; Singer S
Ann Oncol; 2004 Nov; 15(11):1667-72. PubMed ID: 15520069
[TBL] [Abstract][Full Text] [Related]
20. Paediatric non-rhabdomyosarcoma soft tissue sarcomas: the prospective NRSTS 2005 study by the European Pediatric Soft Tissue Sarcoma Study Group (EpSSG).
Ferrari A; van Noesel MM; Brennan B; Zanetti I; Corradini N; Casanova M; Berlanga P; Merks JHM; Alaggio R; Schifflers S; Ramirez-Villar GL; Giraudo C; Burrieza GG; Safwat A; Bisogno G; De Salvo GL; Orbach D
Lancet Child Adolesc Health; 2021 Aug; 5(8):546-558. PubMed ID: 34214481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
